Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,550.00GBp
28 Apr 2017
Change (% chg)

-8.50 (-0.55%)
Prev Close
1,558.50
Open
1,556.00
Day's High
1,558.00
Day's Low
1,544.00
Volume
10,615,813
Avg. Vol
8,645,860
52-wk High
1,745.56
52-wk Low
1,363.00

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 0.97
Market Cap(Mil.): £76,218.15
Shares Outstanding(Mil.): 4,917.30
Dividend: 19.00
Yield (%): --

Financials

  GSK.L Industry Sector
P/E (TTM): 45.34 29.18 30.12
EPS (TTM): 0.34 -- --
ROI: 5.27 13.76 13.28
ROE: 74.13 14.71 14.44

BRIEF-Glaxo Smithkline Consumer Nig reports Q1 group loss before tax of 8.3 mln naira

* Q1 group loss before tax of 8.3 million naira versus profit of 167.5 million naira year ago

Apr 28 2017

UPDATE 2-New GlaxoSmithKline CEO wants fewer, bigger new drug launches

* Q1 adjusted EPS 25.0 pence vs consensus 24.5p (Adds analyst comment, latest shares)

Apr 26 2017

Weak sterling boosts GlaxSmithKline as new CEO takes over

LONDON GlaxoSmithKline's new chief executive reported slightly better than expected first-quarter results on Wednesday, keeping the drugmaker on track to hit financial targets in 2017 as it braces for generic competition to blockbuster lung drug Advair.

Apr 26 2017

Teva's new asthma inhaler poses first competition for GSK's Advair

Teva Pharmaceutical Industries Ltd on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline's best-selling Advair.

Apr 20 2017

UPDATE 2-Teva's new asthma inhaler poses first competition for GSK's Advair

April 20 Teva Pharmaceutical Industries Ltd on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline's best-selling Advair.

Apr 20 2017

Teva launches copy of asthma inhaler Advair

April 20 Teva Pharmaceutical Industries Ltd launched its asthma inhaler and the authorized generic of the drug on Thursday, nearly three months after it got U.S. approval to market a copy of GlaxoSmithKline's best-selling Advair.

Apr 20 2017

BRIEF-GSK seeks Japanese approval for shingles vaccine

* JV between GSK, Daiichi Sankyo submitted new drug application in Japan seeking approval for candidate shingles vaccine, shingrix Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Apr 18 2017

UPDATE 1-Innoviva to review costs, executive pay following Sarissa pressure

April 13 Drug company Innoviva Inc said on Thursday it would undertake a review of its costs, including executive compensation following pressure from activist investor Sarissa Capital Management LP.

Apr 13 2017

OncoMed sinks as cancer drug fails; Bayer opts against licensing drugs

(In this April 10th story, corrects paragraphs 1 and 11 to drop the words "stem cell")

Apr 11 2017

CORRECTED-UPDATE 2-OncoMed sinks as cancer drug fails; Bayer opts against licensing drugs

April 10 OncoMed Pharmaceuticals Inc said it would discontinue a trial testing its experimental therapy demcizumab as an initial treatment for advanced pancreatic cancer, after the addition of the drug to standard-of-care failed a mid-stage study.

Apr 11 2017

More From Around the Web

Earnings vs. Estimates